(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Akerna Corp., Mediaco Holding, and Leap Therapeutics.

The three biggest losers today are Kintara Therapeutics, IMAC Holdings, and Microbot Medical .

Winners today

1. Akerna Corp. (KERNW) – 69.23%

Akerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in the United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a retail analytics platform. In addition, the company operates Solo, a seed-to-sale tagging and tracking software platform, and Trellis, a cultivation and compliance software platform. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.

NASDAQ ended the session with Akerna Corp. rising 69.23% to $0.02 on Tuesday, after five successive sessions in a row of losses. NASDAQ fell 1.63% to $14,765.94, after two sequential sessions in a row of losses, on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, Akerna Corp. has a trailing twelve months EPS of $-0.643.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -363%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 32%, now sitting on 9.82M for the twelve trailing months.

More news about Akerna Corp..

2. Mediaco Holding (MDIA) – 30.36%

MediaCo Holding Inc. owns and operates radio stations in the United States. The company engages in the operation of WQHT-FM and WBLS-FM radio stations in the New York City area. It owns and operates advertising displays, such as bulletins, posters, and digital billboards primarily in Georgia, Alabama, South Carolina, Florida, Kentucky, West Virginia, and Ohio. The company also offers digital advertising and event, which includes sponsorships, ticket sales, licensing, and syndication services. MediaCo Holding Inc. was incorporated in 2019 and is headquartered in New York, New York.

NASDAQ ended the session with Mediaco Holding rising 30.36% to $0.56 on Tuesday, following the last session’s upward trend. NASDAQ fell 1.63% to $14,765.94, after two successive sessions in a row of losses, on what was an all-around negative trend trading session today.

Earnings Per Share

As for profitability, Mediaco Holding has a trailing twelve months EPS of $-0.31.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.61%.

More news about Mediaco Holding.

3. Leap Therapeutics (LPTX) – 20.14%

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

NASDAQ ended the session with Leap Therapeutics rising 20.14% to $4.98 on Tuesday while NASDAQ slid 1.63% to $14,765.94.

Earnings Per Share

As for profitability, Leap Therapeutics has a trailing twelve months EPS of $-4.83.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -114.09%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Leap Therapeutics’s EBITDA is 4.06.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 46% and 80.9%, respectively.

Volume

Today’s last reported volume for Leap Therapeutics is 255419 which is 19.9% below its average volume of 318879.

Moving Average

Leap Therapeutics’s worth is way above its 50-day moving average of $2.33 and way above its 200-day moving average of $3.17.

More news about Leap Therapeutics.

4. Moderna (MRNA) – 14.1%

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Moderna rising 14.1% to $113.47 on Tuesday, following the last session’s upward trend. NASDAQ dropped 1.63% to $14,765.94, after two sequential sessions in a row of losses, on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, Moderna has a trailing twelve months EPS of $-9.23.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.04%.

More news about Moderna.

5. Lion Group Holding Ltd. (LGHL) – 13.45%

Lion Group Holding Ltd., together with its subsidiaries, operates a trading platform in Hong Kong. The company's trading platform offers a range of products and services, including contract for difference trading, insurance brokerage, asset management, and futures and securities brokerage services for investors and institutional clients. It also provides total return swap (TRS) services, which include A-shares and Hong Kong stock basket-linked TRS. Lion Group Holding Ltd. has a strategic partnership with Grandshores Technology Group Limited. The company is headquartered in Kowloon Bay, Hong Kong.

NASDAQ ended the session with Lion Group Holding Ltd. rising 13.45% to $1.35 on Tuesday while NASDAQ fell 1.63% to $14,765.94.

Earnings Per Share

As for profitability, Lion Group Holding Ltd. has a trailing twelve months EPS of $-11.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -32.25%.

Yearly Top and Bottom Value

Lion Group Holding Ltd.’s stock is valued at $1.35 at 16:32 EST, way under its 52-week high of $41.00 and way higher than its 52-week low of $0.86.

Volume

Today’s last reported volume for Lion Group Holding Ltd. is 679745 which is 320.59% above its average volume of 161616.

Moving Average

Lion Group Holding Ltd.’s worth is way above its 50-day moving average of $1.16 and way under its 200-day moving average of $4.56.

More news about Lion Group Holding Ltd..

6. Bionano Genomics (BNGO) – 12.96%

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

NASDAQ ended the session with Bionano Genomics rising 12.96% to $2.14 on Tuesday, after two consecutive sessions in a row of losses. NASDAQ dropped 1.63% to $14,765.94, after two sequential sessions in a row of losses, on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, Bionano Genomics has a trailing twelve months EPS of $-7.17.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -113.43%.

More news about Bionano Genomics.

7. MicroStrategy (MSTR) – 11.39%

MicroStrategy Incorporated provides enterprise analytics software and services in the United States, Canada, Europe, the Middle East, Africa, and internationally. It offers MicroStrategy, an enterprise analytics software platform that enables users to create visualizations, customize apps, and embed analytics directly into workflows; and MicroStrategy Cloud Environment, a managed software-as-a-service solution, which offers always-on threat monitoring and enables rapid analytics development and deployment to deliver security and data privacy requirements. The company also provides MicroStrategy Support that helps customers to achieve their system availability and uptime goals, and to improve the overall experience through highly responsive troubleshooting and proactive technical product support. In addition, it offers MicroStrategy Consulting, which offers customers with architecture and implementation services to help them quickly realize results, as well as helps to achieve returns on investment derived from understanding of data; and MicroStrategy Education that provides free and paid learning options, as well as holds and acquires bitcoin. The company offers its services through enterprise sales force and channel partners. It serves companies from a range of industries, including banking, technology, consulting, manufacturing, insurance, healthcare, and telecommunications, as well as the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

NASDAQ ended the session with MicroStrategy jumping 11.39% to $703.53 on Tuesday, after two successive sessions in a row of losses. NASDAQ slid 1.63% to $14,765.94, after two sequential sessions in a row of losses, on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $2.02.

PE Ratio

MicroStrategy has a trailing twelve months price to earnings ratio of 348.28. Meaning, the purchaser of the share is investing $348.28 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.22%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

MicroStrategy’s EBITDA is 23.55.

Yearly Top and Bottom Value

MicroStrategy’s stock is valued at $703.53 at 16:32 EST, way higher than its 52-week high of $622.58.

Volatility

MicroStrategy’s last week, last month’s, and last quarter’s current intraday variation average was 1.63%, 0.99%, and 3.14%.

MicroStrategy’s highest amplitude of average volatility was 5.74% (last week), 3.18% (last month), and 3.14% (last quarter).

Volume

Today’s last reported volume for MicroStrategy is 1534850 which is 58.27% above its average volume of 969730.

More news about MicroStrategy.

8. Inovio Pharmaceuticals (INO) – 10.75%

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

NASDAQ ended the session with Inovio Pharmaceuticals rising 10.75% to $0.56 on Tuesday, following the last session’s downward trend. NASDAQ slid 1.63% to $14,765.94, after two consecutive sessions in a row of losses, on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-0.63.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -81.3%.

Volume

Today’s last reported volume for Inovio Pharmaceuticals is 5331160 which is 47.77% above its average volume of 3607570.

Revenue Growth

Year-on-year quarterly revenue growth declined by 95.8%, now sitting on 854.02k for the twelve trailing months.

More news about Inovio Pharmaceuticals.

9. American Public Education (APEI) – 10.26%

American Public Education, Inc., together with its subsidiaries, provides online and campus-based postsecondary education and career learning. It operates through three segments: American Public University System, Rasmussen University, and Hondros College of Nursing. The company offers 136 degree programs and 115 certificate programs in various fields of study, including nursing, public health, public administration, and business administration. It also provides nursing-and health sciences-focused postsecondary education, diploma in practical nursing, and an associate degree in nursing. The company was incorporated in 1991 and is headquartered in Charles Town, West Virginia.

NASDAQ ended the session with American Public Education jumping 10.26% to $10.64 on Tuesday while NASDAQ dropped 1.63% to $14,765.94.

Earnings Per Share

As for profitability, American Public Education has a trailing twelve months EPS of $-3.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.4%.

More news about American Public Education.

10. Lion Group Holding Ltd. (LGHLW) – 10.17%

Lion Group Holding Ltd., together with its subsidiaries, operates a trading platform for corporate clients, individual traders, and retail investors. Its trading platform offers a range of products and services comprising contracts for difference trading, insurance brokerage, futures and securities brokerage, total return swap trading, and asset management services. The company's trading platform allows users to trade various futures products on futures exchanges worldwide, including the Chicago Mercantile Exchange, Singapore Exchange, the Hong Kong Futures Exchange, and Eurex Exchange; stocks listed on the New York Stock Exchange, Nasdaq and Hong Kong Stock Exchange; and the People's Republic of China stocks listed on the Shanghai Stock Exchange and Shenzhen Stock Exchange that are eligible for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs. It also creates, mints, and sells the MetaWords NFTs; and operates Lion NFT platform for buying and selling the MetaWords NFTs. The company has a strategic partnership with Dawa Future Graphic Technology Co., Ltd. to develop its Lion World Metaverse project. Lion Group Holding Ltd. was founded in 2015 and is headquartered in Singapore.

NASDAQ ended the session with Lion Group Holding Ltd. rising 10.17% to $0.01 on Tuesday while NASDAQ slid 1.63% to $14,765.94.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -32.25%.

Yearly Top and Bottom Value

Lion Group Holding Ltd.’s stock is valued at $0.01 at 16:32 EST, way above its 52-week high of $0.01.

More news about Lion Group Holding Ltd..

Losers Today

1. Kintara Therapeutics (KTRA) – -12.12%

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.

NASDAQ ended the session with Kintara Therapeutics sliding 12.12% to $0.17 on Tuesday while NASDAQ slid 1.63% to $14,765.94.

Earnings Per Share

As for profitability, Kintara Therapeutics has a trailing twelve months EPS of $-7.71.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -342.86%.

Yearly Top and Bottom Value

Kintara Therapeutics’s stock is valued at $0.17 at 16:32 EST, way below its 52-week high of $9.00 and higher than its 52-week low of $0.16.

Volume

Today’s last reported volume for Kintara Therapeutics is 123841000 which is 4046.32% above its average volume of 2986760.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Kintara Therapeutics’s EBITDA is -5.49.

More news about Kintara Therapeutics.

2. IMAC Holdings (IMACW) – -10%

NASDAQ ended the session with IMAC Holdings sliding 10% to $0.01 on Tuesday, after five successive sessions in a row of losses. NASDAQ slid 1.63% to $14,765.94, after two successive sessions in a row of losses, on what was an all-around down trend trading session today.

Yearly Top and Bottom Value

IMAC Holdings’s stock is valued at $0.01 at 16:32 EST, way higher than its 52-week high of $0.01.

More news about IMAC Holdings.

3. Microbot Medical (MBOT) – -9.6%

Microbot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, a robotic system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination. In addition, it provides One & Done Technology, an endovascular robotic system for a range of applications in cardiovascular, peripheral vascular, and neurovascular spaces; and NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. Further, the company offers ViRob, an autonomous crawling micro-robot which can be controlled remotely to navigate and crawl in different natural spaces within the human body, including blood vessels, digestive tract, and respiratory system, as well as artificial spaces, such as shunts, catheters, ports, etc. Additionally, it provides ipCAT, a disposable self-propelled locomotive device that is designed to advance in tubular anatomies. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is headquartered in Hingham, Massachusetts.

NASDAQ ended the session with Microbot Medical falling 9.6% to $1.48 on Tuesday, following the last session’s downward trend. NASDAQ slid 1.63% to $14,765.94, after two sequential sessions in a row of losses, on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, Microbot Medical has a trailing twelve months EPS of $-1.17.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -164.21%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 39% and 47.2%, respectively.

Volume

Today’s last reported volume for Microbot Medical is 621389 which is 30.4% below its average volume of 892906.

Yearly Top and Bottom Value

Microbot Medical ‘s stock is valued at $1.48 at 16:32 EST, way under its 52-week high of $4.37 and way above its 52-week low of $1.00.

More news about Microbot Medical .

4. Ideanomics (IDEX) – -8.72%

Ideanomics, Inc. focuses on driving the adoption of commercial electric vehicles, associated energy consumption, and developing financial services and fintech products. Its Ideanomics Mobility division facilitates the adoption of electric vehicles by commercial fleet operators. This division also offers solutions for the procurement, financing, charging, and energy management needs for fleet operators of commercial electric vehicles. The company's Ideanomics Capital division provides fintech services, which focuses on the enhancement of efficiency, transparency, and profitability for the financial services industry. Ideanomics, Inc. was incorporated in 2004 and is headquartered in New York, New York.

NASDAQ ended the session with Ideanomics sliding 8.72% to $1.99 on Tuesday while NASDAQ fell 1.63% to $14,765.94.

Earnings Per Share

As for profitability, Ideanomics has a trailing twelve months EPS of $-55.95.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -233.53%.

Moving Average

Ideanomics’s value is above its 50-day moving average of $1.98 and way below its 200-day moving average of $6.01.

More news about Ideanomics.

5. Li Auto (LI) – -7.37%

Li Auto Inc., through its subsidiaries, designs, develops, manufactures, and sells new energy vehicles in the People's Republic of China. The company provides Li ONE and Li L series smart electric vehicles. It also offers sales and after sales management, and technology development and corporate management services, as well as purchases manufacturing equipment. The company offers its products through online and offline channels. The company was formerly known as Leading Ideal Inc. and changed its name to Li Auto Inc. in July 2020. Li Auto Inc. was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Li Auto sliding 7.37% to $34.67 on Tuesday while NASDAQ dropped 1.63% to $14,765.94.

Nio, Xpeng (xpev) & Li Auto (li) report 2023 deliveriesAs of Dec 31, 2023, Li Auto reached a significant milestone by surpassing 600,000 cumulative vehicle deliveries. , At the end of 2023, Li Auto operated 467 retail stores in 140 cities, along with 360 servicing centers and authorized body and paint shops, extending its presence to 209 cities.

Earnings Per Share

As for profitability, Li Auto has a trailing twelve months EPS of $0.23.

PE Ratio

Li Auto has a trailing twelve months price to earnings ratio of 150.74. Meaning, the purchaser of the share is investing $150.74 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.89%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 271.2%, now sitting on 99.77B for the twelve trailing months.

Yearly Top and Bottom Value

Li Auto’s stock is valued at $34.67 at 16:32 EST, way below its 52-week high of $47.33 and way above its 52-week low of $17.90.

More news about Li Auto.

6. Immatics N.V. (IMTXW) – -7.3%

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

NASDAQ ended the session with Immatics N.V. falling 7.3% to $2.92 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ dropped 1.63% to $14,765.94, after two consecutive sessions in a row of losses, on what was an all-around bearish trend exchanging session today.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -46.61%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 60.7%, now sitting on 75.72M for the twelve trailing months.

Yearly Top and Bottom Value

Immatics N.V.’s stock is valued at $2.92 at 16:32 EST, way under its 52-week high of $3.26 and higher than its 52-week low of $2.80.

More news about Immatics N.V..

7. Beyond Meat (BYND) – -6.97%

Beyond Meat, Inc. develops, manufactures, markets, and sells plant-based meat products in the United States and internationally. The company sells a range of plant-based meat products across the platforms of beef, pork, and poultry. It sells its products through grocery, mass merchandiser, club, convenience, and natural retailer channels, as well as various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company was formerly known as Savage River, Inc. and changed its name to Beyond Meat, Inc. in September 2018. Beyond Meat, Inc. was founded in 2009 and is headquartered in El Segundo, California.

NASDAQ ended the session with Beyond Meat sliding 6.97% to $8.28 on Tuesday while NASDAQ dropped 1.63% to $14,765.94.

Earnings Per Share

As for profitability, Beyond Meat has a trailing twelve months EPS of $-3.89.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Beyond Meat’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth declined by 8.7%, now sitting on 349.64M for the twelve trailing months.

More news about Beyond Meat.

8. Coinbase (COIN) – -6.74%

Coinbase Global, Inc. provides financial infrastructure and technology for the cryptoeconomy in the United States and internationally. It offers the primary financial account in the cryptoeconomy for consumers; a marketplace with a pool of liquidity for transacting in crypto assets for institutions; and technology and services that enable developers to build crypto-based applications and securely accept crypto assets as payment. The company was founded in 2012 and is based in Wilmington, Delaware.

NASDAQ ended the session with Coinbase sliding 6.74% to $162.20 on Tuesday, after two sequential sessions in a row of losses. NASDAQ slid 1.63% to $14,765.94, after two consecutive sessions in a row of losses, on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, Coinbase has a trailing twelve months EPS of $-3.2.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.09%.

Moving Average

Coinbase’s value is way higher than its 50-day moving average of $79.78 and way above its 200-day moving average of $66.85.

More news about Coinbase.

9. Jaguar Health (JAGX) – -6.49%

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.

NASDAQ ended the session with Jaguar Health falling 6.49% to $0.15 on Tuesday while NASDAQ fell 1.63% to $14,765.94.

Earnings Per Share

As for profitability, Jaguar Health has a trailing twelve months EPS of $-0.87.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1628.08%.

More news about Jaguar Health.

10. Kodiak Sciences (KOD) – -6.17%

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.

NASDAQ ended the session with Kodiak Sciences sliding 6.17% to $3.04 on Tuesday while NASDAQ fell 1.63% to $14,765.94.

Earnings Per Share

As for profitability, Kodiak Sciences has a trailing twelve months EPS of $-5.19.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.42%.

Volume

Today’s last reported volume for Kodiak Sciences is 352882 which is 63.26% below its average volume of 960640.

Moving Average

Kodiak Sciences’s worth is way above its 50-day moving average of $2.36 and way under its 200-day moving average of $4.03.

Yearly Top and Bottom Value

Kodiak Sciences’s stock is valued at $3.04 at 16:32 EST, way below its 52-week high of $9.80 and way above its 52-week low of $1.37.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Kodiak Sciences’s EBITDA is 4.64.

More news about Kodiak Sciences.

Stay up to date with our winners and losers daily report